Clinical Trial

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 11, 2023 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of tislelizumab combined with concurrent chemoradiotherapy in first-line treatment of stage IIIC2 cervical cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-08-22.
Status change: Not Yet Recruiting → Recruiting 2023-09-08
Trial Details
NCT Number NCT05511623
Lead Sponsor First Affiliated Hospital of Guangxi Medical University
Conditions Cervical Cancer
Enrollment 112 participants
Start Date 2022-09-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-09-11